Tamibarotene is under clinical development by Toko Pharmaceutical Industries and currently in Phase II for Polycystic Kidney Disease. According to GlobalData, Phase II drugs for Polycystic Kidney Disease have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tamibarotene’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tamibarotene overview
Tamibarotene (Amnolake) is a synthetic retinoid acts as anti-neoplastic agent. It is formulated as tablets for oral route of administration. It is used for the treatment of relapsed or refractory acute promyelocytic leukemia.
The drug candidate is under development for the treatment of acute promyelocytic leukemia in China.
It is under development for autosomal dominant polycystic kidney disease (ADPKD), relapsed and refractory, newly diagnosed acute myelocytic leukemia, myelodysplastic syndrome, neutropenia, neuroblastoma, germ cell tumor, chronic myelomonocytic leukemia and sarcomas. It was also under development for acute promyelocytic leukemia in the U.S. and EU , breast cancer and hepatocellular carcinoma.
Toko Pharmaceutical Industries overview
Toko Pharmaceutical Industries operates in pharmaceutical and healthcare industry. It is headquartered in Japan.
For a complete picture of Tamibarotene’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
